Bellone M - Search Results

1

Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.

Degl'Innocenti E, Grioni M, Capuano G, Jachetti E, Freschi M, Bertilaccio MT, Hess-Michelini R, Doglioni C, Bellone M. Degl'Innocenti E, et al. Among authors: bellone m. Cancer Res. 2008 Jan 1;68(1):292-300. doi: 10.1158/0008-5472.CAN-07-2429. Cancer Res. 2008. PMID: 18172322

2

B7.1 expression on tumor cells circumvents the need of professional antigen presentation for in vitro propagation of cytotoxic T cell lines.

Iezzi G, Protti MP, Rugarli C, Bellone M. Iezzi G, et al. Among authors: bellone m. Cancer Res. 1996 Jan 1;56(1):11-5. Cancer Res. 1996. PMID: 8548749

3

Particulate naturally processed peptides prime a cytotoxic response against human melanoma in vitro.

Protti MP, Imro MA, Manfredi AA, Consogno G, Heltai S, Arcelloni C, Bellone M, Dellabona P, Casorati G, Rugarli C. Protti MP, et al. Among authors: bellone m. Cancer Res. 1996 Mar 15;56(6):1210-3. Cancer Res. 1996. PMID: 8640799

4

Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells.

Bellone M, Iezzi G, Martin-Fontecha A, Rivolta L, Manfredi AA, Protti MP, Freschi M, Dellabona P, Casorati G, Rugarli C. Bellone M, et al. J Immunol. 1997 Jan 15;158(2):783-9. J Immunol. 1997. PMID: 8992995

5

The immunogenicity of experimental tumors is strongly biased by the expression of dominant viral cytotoxic T-lymphocyte epitopes.

Iezzi G, Rivolta L, Ronchetti A, Martin-Fontecha A, Rosato A, Protti MP, Sabbadini MG, Bellone M. Iezzi G, et al. Among authors: bellone m. Cancer Res. 1997 Jul 1;57(13):2564-8. Cancer Res. 1997. PMID: 9205054

6

Major histocompatibility complex class I restricted cytotoxic T cells specific for natural melanoma peptides recognize unidentified shared melanoma antigen(s).

Imro MA, Manici S, Russo V, Consogno G, Bellone M, Rugarli C, Traversari C, Protti MP. Imro MA, et al. Among authors: bellone m. Cancer Res. 1999 May 15;59(10):2287-91. Cancer Res. 1999. PMID: 10344730

7

Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.

Moro M, Gasparri AM, Pagano S, Bellone M, Tornaghi P, Veglia F, Corti A, Casorati G, Dellabona P. Moro M, et al. Among authors: bellone m. Cancer Res. 1999 Jun 1;59(11):2650-6. Cancer Res. 1999. PMID: 10363988

8

Apoptosis-dependent subversion of the T-lymphocyte epitope hierarchy in lymphoma cells.

Castiglioni P, Martin-Fontecha A, Milan G, Tomajer V, Magni F, Michaelsson J, Rugarli C, Rosato A, Bellone M. Castiglioni P, et al. Among authors: bellone m. Cancer Res. 2002 Feb 15;62(4):1116-22. Cancer Res. 2002. PMID: 11861391

9

Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes.

Camporeale A, Boni A, Iezzi G, Degl'Innocenti E, Grioni M, Mondino A, Bellone M. Camporeale A, et al. Among authors: bellone m. Cancer Res. 2003 Jul 1;63(13):3688-94. Cancer Res. 2003. PMID: 12839960

10

Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin.

Sacchi A, Gasparri A, Curnis F, Bellone M, Corti A. Sacchi A, et al. Among authors: bellone m. Cancer Res. 2004 Oct 1;64(19):7150-5. doi: 10.1158/0008-5472.CAN-04-1445. Cancer Res. 2004. PMID: 15466213

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

185 results

Search Page

Filters